spacer
home > ebr > summer 2019 > an answerable challenge
PUBLICATIONS
European Biopharmaceutical Review

An Answerable Challenge

While cancer and cardiovascular diseases continue to hold the top ranks of the causes of mortality in Europe and North America, we have become accustomed to the burden of disease from neurodegenerative conditions increasing, mostly as a consequence of population ageing. If one were to cast the net wider (not only focusing on conditions that have neurodegeneration as a cause, but all neurological disorders), one would see that these were the leading cause of disability-adjusted life years − which refer to the sum of lost life years and years lived with disability − worldwide in 2016. While infectious causes have decreased over the past 25 years, stroke and dementia continue to loom large across the globe (1). In high-income countries, these two conditions rank second and third respectively in terms of crude death rate.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
While cancer and cardiovascular diseases continue to hold the top ranks of the causes of mortality in Europe and North Dr Hermann Mucke is the owner and Chief Executive of H.M. Pharma Consultancy, a globally acting provider of consulting services to the pharmaceutical industry and academia, with headquarters in Vienna, Austria. After earning his Masterís and PhD degrees in biochemistry and molecular biology, he spent four years at the University of Vienna, Austria, before moving to industry, finally becoming an entrepreneur in 2000 when he set up his life sciences consultancy. An expert in drug repurposing, patenting, and knowledge management, Hermann has assisted companies of all sizes over the past 20 years.
spacer
Dr Hermann Mucke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Drive for generics sees Korea increasingly attractive to international pharma

Amsterdam, 31st July 2019: Already home to more than 40 pharmaceutical multinationals, Korea is on course to become a global biotech and pharmaceutical hub by 2025, driven by the surge of international partnerships, biosimilars, an expansion in the export of finished formulations and a robust generics market.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement